Dentsply Sirona account plan
dental products technologies solutions
At a glance
Dentsply Sirona makes dental equipment, consumables, implants, aligners and continence care products, with $3,680 million of FY2025 net sales.
Dentsply Sirona describes itself as the world's largest diversified manufacturer of professional dental products and technologies, plus continence care products through Wellspect. It is headquartered in Charlotte, North Carolina, listed on Nasdaq (XRAY) and sells in approximately 140 countries, about two-thirds of its dental products through third-party distributors. FY2025 net sales were $3,680 million, down 3.0% as reported, with a net loss of $598 million after $650 million of impairments. It had approximately 14,000 employees at December 31, 2025. The company is six months into a 24-month Return to Growth action plan led by CEO Dan Scavilla.
Business units
Essential Dental Solutions
about 40% of FY2025 net sales ($1,469 million)Endodontic, restorative and preventive consumables and small equipment, the main profit contributor with $514 million of FY2025 segment adjusted operating income. Q3 2026 sales fell 4.0% to $343 million on EMEA distributor destocking, while U.S. Endo returned to growth.
Connected Technology Solutions
about 28% of FY2025 net sales ($1,036 million)Imaging, treatment centers, handpieces and CAD/CAM including intraoral scanners and the CEREC chairside system, connected through the DS Core cloud platform. CAD/CAM volumes in the U.S. are under competitive and pricing pressure; Q3 2026 sales fell 11.0% to $230 million with a $3 million segment loss.
Orthodontic and Implant Solutions
about 23% of FY2025 net sales ($850 million)Implant systems, prosthetics, bone regeneration and SureSmile clear aligners. Premium implant volumes are down and the Byte direct-to-consumer aligner is no longer offered to new patients; Q3 2026 sales fell 16.6% to $171 million, while MIS value implants grew double digits in the U.S.
Wellspect Healthcare
about 9% of FY2025 net sales ($325 million)Continence care catheters and irrigation systems for urinary and bowel management, made in Sweden and Turkey. It is the only growing segment: Q3 2026 sales rose 10.1% to $92 million, led by Surity in the U.S., now qualified for traditional Medicare coverage.
Strategic priorities
- Return to Growth action plan
- A 24-month plan puts customers first, better execution and investment where growth is greatest; the U.S. is the top priority, with the aim to exit 2026 with U.S. growth.
- U.S. commercial reset
- Seven new North American distribution agreements were signed this year, quota-carrying field vacancies fell to the mid-single digits from more than 20%, and the MIS sales force is to nearly double by year-end; a new team targets Dental Support Organizations.
- Innovation and DS Core
- R&D is planned at about 5% of net sales from 2026, focused on DS Core, clinical AI and next-generation intraoral scanners; implants and ortho on DS Core are targeted for late 2027 subject to FDA approval.
- Clinical education
- Clinical education spend in North America in H2 2026 is six times last year's level, including more than 160 Endo courses.
- Cost savings and debt reduction
- The 2026 Plan targets approximately $100 million of annualized savings (first set at approximately $120 million), partly reinvested; net debt to EBITDA was 3.4x and debt reduction remains a priority.
Latest results
In Q3 2026 (quarter to September 30, 2026) net sales were $836 million, down 7.6% as reported from $904 million; excluding Byte, planned dealer inventory reductions and one-offs they fell 3.8%. Nine-month sales were $2,614 million, down 3.9%. Gross margin rose to 52.9% from 48.8%, helped by a $39 million inventory estimate change, and the net loss narrowed to $2 million from $427 million. Full-year 2026 guidance was cut to approximately $3.5 billion of sales and adjusted EPS of $1.20-$1.30, from $1.40-$1.50. No 2027 guidance has been given.
Investments and deals
- 2026 capital expenditures
- 2026 capex was raised to $165-185 million, covering supply chain equipment, capacity for product innovation, DS Core enhancements and a new global ERP.
- 2026 restructuring plan
- Approved February 24, 2026; $54 million of charges incurred so far, with total charges now expected at $60-65 million.
- R&D increase
- R&D rose 14.9% to $42 million in Q3 2026 (5.0% of sales), mostly for DS Core, under a new stage-gate product development process.
- Wellspect growth
- Investment in Wellspect rose 15% to pursue the $7 billion urinary management market, completing the U.S. Surity portfolio.
Challenges and risks
- Declining sales and impairments
- FY2025 sales fell 3.0% with $650 million of goodwill and intangible impairments; the Implant & Prosthetic Solutions goodwill was fully written off.
- Distributor destocking
- EMEA distributors are cutting inventory from about 12 weeks to about 8, and Henry Schein accounted for 13% of 2025 net sales, creating concentration and ordering variability.
- CAD/CAM and implant pricing pressure
- CAD/CAM faces pricing pressure from lower-cost entrants in EMEA and competitive pressure in the U.S.; premium implant volumes are down.
- Tariffs and geopolitics
- Much of the U.S. equipment is made in Europe; Russia and Ukraine are about 3% of sales, implants are made in two Israeli plants, and Middle East conflict lowered revenue in some markets.
- Leverage
- Net debt was $2,002 million at end 2025, the credit agreement was amended for covenant flexibility and the quarterly dividend was eliminated from Q1 2026.
What leadership says
“We are making progress, but our results are not yet where they need to be.”
“We're making progress, but this is still a turnaround.”
“We return to growth, we maximize profitability, and we maximize cash generation.”
“US remains a top focus, and we are encouraged by the green shoots we are seeing.”
Where a supplier can help
- Sales enablement and training
- Tied to the U.S. commercial reset: hiring, certification and training support for a sales force rebuilding vacancies and nearly doubling MIS reps.
- Distributor activation
- Tied to the seven new North American distribution agreements and distributor destocking: channel management, incentive and inventory visibility tools.
- ERP and finance systems
- Tied to the new global ERP in the 2026 capex plan and the new financial consolidation system: implementation and forecasting support.
- Software and AI for DS Core
- Tied to the R&D push on DS Core and clinical AI: cloud, AI and software engineering partners for connected dentistry.
- Cost reduction
- Tied to the 2026 Plan savings and debt reduction priority: lean operations, procurement and automation offers that free cash.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Dentsply Sirona?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Dentsply Sirona Form 10-K for fiscal year 2025
- Dentsply Sirona describes itself as the world's largest diversified manufacturer of professional dental products and technologies (139-year history), headquartered in Charlotte, North Carolina, listed on Nasdaq (XRAY), selling in approximately 140 countries with approximately 14,000 employees (approximately 3,000 in the U.S.) at December 31, 2025.
- FY2025 net sales were $3,680 million, down 3.0% as reported and 4.3% in constant currency; net loss was $598 million (diluted loss per share $3.00) after $650 million of goodwill and intangible asset impairments; operating cash flow fell to $235 million from $461 million.
- Four reportable segments: Essential Dental Solutions ($1,469 million, the profit engine with $514 million segment adjusted operating income), Connected Technology Solutions ($1,036 million, $52 million), Orthodontic and Implant Solutions ($850 million, $108 million) and Wellspect Healthcare ($325 million, $102 million).
- By region: United States $1,182 million (down 12.3%), Europe $1,576 million (up 3.8%), Rest of World $922 million; Germany alone $422 million.
- Weak spots: CAD/CAM volumes in the U.S. under competitive and pricing pressure, premium implants (the Implant & Prosthetic Solutions reporting unit's goodwill was fully written off by year-end), and the Byte direct-to-consumer aligner business, no longer offered to new patients.
- About two-thirds of dental consumables and equipment are sold through third-party distributors; Henry Schein accounted for 13% of 2025 net sales. A new non-exclusive U.S. equipment distribution agreement was signed with Patterson Dental in January 2026.
- Plans: R&D to rise from about 4% to about 5% of net sales from 2026; a 2026 restructuring plan (approved February 24, 2026) targets approximately $120 million of annualized savings, partly reinvested in innovation, clinical education and sales training focused on connected dentistry; 2026 capex of approximately $125-150 million, including a new global ERP.
- Balance sheet: net debt $2,002 million, net debt to total capitalization 59.9%; $550 million of 8.375% junior subordinated notes issued in June 2025; quarterly dividend eliminated from Q1 2026.
- Risks flagged: tariffs (much of the U.S. equipment is made in Europe), distributor concentration and inventory swings, further impairments, Russia/Ukraine (about 3% of sales) and Israel-made implants, EU MDR certification, cyber and debt covenants.
- Dentsply Sirona Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026) net sales were $836 million, down 7.6% as reported from $904 million; nine-month sales were $2,614 million, down 3.9%.
- Segment Q3 sales: Essential Dental Solutions $343 million, Connected Technology Solutions $230 million, Orthodontic and Implant Solutions $171 million, Wellspect Healthcare $92 million (up 10.1%, the only growing segment).
- Gross margin rose to 52.9% from 48.8%, driven by a $39 million reduction to cost of products sold from a change in the estimate of intercompany profit in inventory; net loss was $2 million vs $427 million a year earlier, when $262 million of impairments were booked.
- Segment adjusted operating income: EDS $141 million (up 21.6%), Wellspect $25 million, CTS a $3 million loss and OIS a $1 million loss.
- Drivers: lower implant volumes and the absence of Byte, lower CAD/CAM volumes in the Americas after a strategic shift in distributor inventory management, and lower endodontic volumes in EMEA as distributors destocked.
- R&D rose 14.9% to $42 million (5.0% of sales), mostly for DS Core; SG&A rose on clinical education training and bad debt.
- 2026 Plan: $54 million of charges incurred so far; total now expected at $60-65 million for approximately $100 million of annualized savings. 2026 capex raised to $165-185 million (supply chain, DS Core, ERP).
- Balance sheet: $195 million cash, $215 million of commercial paper, credit agreement amended for covenant flexibility; $25 million of buybacks year to date; a $75 million settlement of the 2024 securities litigation agreed in principle, funded by insurers.
- Dentsply Sirona Q3 2026 earnings call transcript
- CEO Dan Scavilla said the Return to Growth action plan advanced in Q3 but "our results are not yet where they need to be"; full-year 2026 sales guidance cut to approximately $3.5 billion and adjusted EPS to $1.20-$1.30 (from $1.40-$1.50), excluding a $0.17 tariff-refund gain.
- CFO John Fortson: Q3 revenue $836 million, down 7.6% reported and 7% constant currency; excluding Byte, about $10 million of planned dealer inventory reductions and one-offs, down 3.8%. Adjusted EPS $0.29; net debt to EBITDA 3.4x; debt reduction remains a priority.
- A $39 million pre-tax ($30 million after tax) inventory accounting benefit from a new consolidation system is kept in guidance; Scavilla says other one-time items offset most of it.
- Green shoots: Wellspect record sales up 10% to $92 million (Surity in the U.S., now qualified for traditional Medicare coverage), U.S. MIS value implants up double digits, U.S. Endo up 4% and back to growth for the first time since Q2 2025.
- Pressure: EMEA distributor destocking, Middle East conflict, higher freight, CAD/CAM pricing pressure from lower-cost entrants in EMEA; premium implant volumes down.
- Commercial build-out: seven new North American distribution agreements this year, quota-carrying field vacancies down to mid-single digits from more than 20%, plan to nearly double the MIS sales force by year-end, a new DSO enterprise team.
- Clinical education in North America in H2 2026 is six times last year's level; R&D up about 20% through September; Primescan Connect launched on DS Core; OSSIX Plus back in the U.S. and Canada.
- Transformation office drives the approximately $120 million 2026 savings initiative; no 2027 guidance yet - the "next chapters" of the plan to be presented after board alignment.
- Dentsply Sirona Q2 2026 earnings call transcript
- Q2 2026 revenue $898 million, down 4.1% as reported and 6.3% in constant currency (down 3.6% excluding Byte and about $8 million of planned dealer inventory reduction); adjusted EPS flat at $0.52, including $44 million of tariff refunds worth $0.17 per share.
- New CFO John Fortson (joined July 20) set three priorities: "We return to growth, we maximize profitability, and we maximize cash generation."
- 2026 guidance maintained at $3.5-3.6 billion of sales and $1.40-$1.50 adjusted EPS; improvement expected to be weighted to Q4 as investments in sales force, clinical education and R&D begin to show.
- Segments: CTS $239 million (CAD/CAM down mid-single digits, APAC up double digits), EDS $376 million (EMEA dealers cutting inventory from about 12 weeks to about 8), OIS $197 million (premium implants weak in the Americas and APAC; SureSmile $40 million), Wellspect $86 million, up 7.1%.
- CEO Dan Scavilla six months into a 24-month Return to Growth action plan: "this is still a turnaround"; the U.S. is the top priority, aiming to exit 2026 with U.S. growth.
- Actions: more than 1,000 clinicians at the Global Implant Summit, recertification of every U.S. implant rep, four European DSO groups implementing DS Core, new dealer partnerships (Atlanta Dental, Nashville Dental, Medline Sinclair in Canada).
- First buyback since Q3 2024 (1.3 million shares below $10); net debt to EBITDA 3.2x; debt reduction prioritised.
- Product roadmap: high, mid and low tiers of next-generation intraoral scanners; implants and ortho on DS Core targeted for late 2027 subject to FDA approval; growth by organic and inorganic routes.
Questions about Dentsply Sirona
What does Dentsply Sirona do?
It develops, manufactures and markets dental equipment, cloud-enabled software, dental consumables, implants and clear aligners, plus continence care products through Wellspect.
What is Dentsply Sirona's revenue?
FY2025 net sales were $3,680 million, down 3.0% as reported. 2026 guidance is approximately $3.5 billion.
How many employees does Dentsply Sirona have?
Approximately 14,000 employees at December 31, 2025, approximately 3,000 of them in the U.S.
What is Dentsply Sirona's strategy?
A 24-month Return to Growth action plan focused on returning the U.S. to growth, sales force and clinical education investment, DS Core innovation, cost savings and debt reduction.
Who leads Dentsply Sirona?
Dan Scavilla is President and Chief Executive Officer, John Fortson is EVP and Chief Financial Officer, and Gregory T. Lucier is Chairman of the Board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)